×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
ATXS – astria therapeutics, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
ATXS
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
12/11
08:22 am
atxs
Astria Therapeutics Announces Positive Final Results from Target Enrollment in the ALPHA-STAR Phase 1b/2 Trial of Navenibart for HAE [Yahoo! Finance]
Medium
Report
Astria Therapeutics Announces Positive Final Results from Target Enrollment in the ALPHA-STAR Phase 1b/2 Trial of Navenibart for HAE [Yahoo! Finance]
12/11
08:00 am
atxs
Astria Therapeutics Announces Positive Final Results from Target Enrollment in the ALPHA-STAR Phase 1b/2 Trial of Navenibart for HAE
Medium
Report
Astria Therapeutics Announces Positive Final Results from Target Enrollment in the ALPHA-STAR Phase 1b/2 Trial of Navenibart for HAE
12/10
12:21 pm
atxs
Astria Therapeutics, Inc. (NASDAQ: ATXS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $16.00 price target on the stock.
Low
Report
Astria Therapeutics, Inc. (NASDAQ: ATXS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $16.00 price target on the stock.
12/10
08:20 am
atxs
Astria Therapeutics Announces FDA Clearance of IND Application for STAR-0310, a Monoclonal Antibody OX40 Antagonist for the Treatment of Atopic Dermatitis [Yahoo! Finance]
Medium
Report
Astria Therapeutics Announces FDA Clearance of IND Application for STAR-0310, a Monoclonal Antibody OX40 Antagonist for the Treatment of Atopic Dermatitis [Yahoo! Finance]
12/10
08:00 am
atxs
Astria Therapeutics Announces FDA Clearance of IND Application for STAR-0310, a Monoclonal Antibody OX40 Antagonist for the Treatment of Atopic Dermatitis
Low
Report
Astria Therapeutics Announces FDA Clearance of IND Application for STAR-0310, a Monoclonal Antibody OX40 Antagonist for the Treatment of Atopic Dermatitis
12/3
04:10 pm
atxs
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Low
Report
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
11/14
01:34 pm
atxs
Astria Therapeutics, Inc. (NASDAQ: ATXS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $16.00 price target on the stock.
Medium
Report
Astria Therapeutics, Inc. (NASDAQ: ATXS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $16.00 price target on the stock.
11/14
08:23 am
atxs
Astria Therapeutics, Inc. (NASDAQ: ATXS) had its price target raised by analysts at Oppenheimer Holdings Inc. from $26.00 to $28.00. They now have an "outperform" rating on the stock.
Medium
Report
Astria Therapeutics, Inc. (NASDAQ: ATXS) had its price target raised by analysts at Oppenheimer Holdings Inc. from $26.00 to $28.00. They now have an "outperform" rating on the stock.
Date
Time
Symbol
Company Name
Action
%Chg
11/13/2024
04:10 pm
atxs
astria therapeutics, inc.
IN-LINE
Report
-4.9%
astria therapeutics, inc.
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
12/19
04:06 pm
atxs
Form 8-K Astria Therapeutics, For: Dec 17
Low
Report
Form 8-K Astria Therapeutics, For: Dec 17
11/14
05:46 pm
atxs
Form SC 13G/A Astria Therapeutics, Filed by: RA CAPITAL MANAGEMENT, L.P.
High
Report
Form SC 13G/A Astria Therapeutics, Filed by: RA CAPITAL MANAGEMENT, L.P.
11/14
05:46 pm
atxs
Form SC 13G/A Astria Therapeutics, Filed by: Venrock Healthcare Capital Partners III, L.P.
High
Report
Form SC 13G/A Astria Therapeutics, Filed by: Venrock Healthcare Capital Partners III, L.P.
11/14
04:42 pm
atxs
Form SC 13D/A Astria Therapeutics, Filed by: PERCEPTIVE ADVISORS LLC
High
Report
Form SC 13D/A Astria Therapeutics, Filed by: PERCEPTIVE ADVISORS LLC
11/14
04:16 pm
atxs
Form SC 13G/A Astria Therapeutics, Filed by: Fairmount Funds Management LLC
Medium
Report
Form SC 13G/A Astria Therapeutics, Filed by: Fairmount Funds Management LLC
11/14
12:04 pm
atxs
Form SC 13G Astria Therapeutics, Filed by: Vestal Point Capital, LP
Medium
Report
Form SC 13G Astria Therapeutics, Filed by: Vestal Point Capital, LP
11/13
04:22 pm
atxs
Form SC 13G/A Astria Therapeutics, Filed by: TCG Crossover GP II, LLC
Medium
Report
Form SC 13G/A Astria Therapeutics, Filed by: TCG Crossover GP II, LLC
11/13
04:02 pm
atxs
Form 10-Q Astria Therapeutics, For: Sep 30
Medium
Report
Form 10-Q Astria Therapeutics, For: Sep 30
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
TOP News Decliners
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: